FibroGen Inc (FGEN) Expected to Announce Quarterly Sales of $51.58 Million
Analysts predict that FibroGen Inc (NASDAQ:FGEN) will announce $51.58 million in sales for the current quarter, according to Zacks. Five analysts have issued estimates for FibroGen’s earnings. The highest sales estimate is $119.30 million and the lowest is $18.60 million. FibroGen posted sales of $43.95 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 17.4%. The business is scheduled to announce its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that FibroGen will report full year sales of $235.25 million for the current financial year, with estimates ranging from $192.50 million to $292.00 million. For the next fiscal year, analysts anticipate that the company will report sales of $310.87 million, with estimates ranging from $125.40 million to $505.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow FibroGen.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.15. FibroGen had a negative net margin of 44.14% and a negative return on equity of 17.71%. The firm had revenue of $23.90 million for the quarter, compared to analyst estimates of $20.44 million. During the same period in the prior year, the firm posted ($0.50) earnings per share. The company’s quarterly revenue was down 25.1% compared to the same quarter last year.
NASDAQ FGEN traded down $0.52 on Friday, hitting $35.13. 593,183 shares of the stock were exchanged, compared to its average volume of 767,855. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.09. FibroGen has a 52 week low of $33.51 and a 52 week high of $68.55. The firm has a market capitalization of $3.07 billion, a P/E ratio of -34.11 and a beta of 1.60.
In other news, Director James A. Schoeneck sold 2,000 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $54.74, for a total value of $109,480.00. Following the transaction, the director now directly owns 29,700 shares of the company’s stock, valued at $1,625,778. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $55.65, for a total transaction of $2,205,743.40. Following the completion of the transaction, the chief executive officer now directly owns 2,619,572 shares in the company, valued at $145,779,181.80. The disclosure for this sale can be found here. Insiders sold 231,791 shares of company stock worth $11,809,225 over the last three months. Insiders own 8.96% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC raised its position in shares of FibroGen by 2.8% in the first quarter. FMR LLC now owns 10,029,786 shares of the biopharmaceutical company’s stock valued at $545,118,000 after purchasing an additional 269,570 shares during the period. Vanguard Group Inc raised its position in shares of FibroGen by 1.8% in the third quarter. Vanguard Group Inc now owns 6,921,874 shares of the biopharmaceutical company’s stock valued at $420,503,000 after purchasing an additional 125,186 shares during the period. Janus Henderson Group PLC raised its position in shares of FibroGen by 27.3% in the first quarter. Janus Henderson Group PLC now owns 2,208,759 shares of the biopharmaceutical company’s stock valued at $120,046,000 after purchasing an additional 473,042 shares during the period. Hillhouse Capital Advisors Ltd. bought a new position in shares of FibroGen in the fourth quarter valued at about $92,712,000. Finally, First Trust Advisors LP raised its position in shares of FibroGen by 11.3% in the first quarter. First Trust Advisors LP now owns 1,900,460 shares of the biopharmaceutical company’s stock valued at $103,290,000 after purchasing an additional 193,038 shares during the period. 67.15% of the stock is currently owned by institutional investors.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Story: Forex
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.